Current partner codePEPTIDESDE
PeptideStat
Menu

Vendors

Compare pricesVendor directoryVendor reviewsDiscount codesLab tests & COAs

Research

ResearchDatabaseClinical trials

Tools

All calculatorsReconstitutionAccumulationUnit converterPeptide chemistry
NCT02045264·Phase 1·INTERVENTIONAL

Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers

IcatibantInflammationPainCompleted

Status

Completed

Phase

Phase 1

Enrollment

12

Locations

1

Results

Posted

Publications

0

Study summary

What the protocol is testing.

This is a single-dose study to evaluate the pharmacokinetics, safety, and tolerability of icatibant administered to adult Japanese subjects.

Full detailed description

Icatibant has been studied for the treatment of acute attacks of hereditary angioedema (HAE), an autosomal dominant disorder characterized by recurrent and self-limiting episodes of edema of the skin, larynx, and gastrointestinal tract. The most serious manifestation of an HAE attack is laryngeal edema, causing obstruction of the upper airways that may lead to death by asphyxiation if undiagnosed and/or untreated. Icatibant has been approved in over 40 countries around the world including the United States (US) and Europe for the treatment of acute attacks of hereditary angioedema (HAE) in adults. This study is being conducted to evaluate the safety and tolerability of icatibant in a Japanese population and to evaluate whether race/ethnicity impacts the pharmacokinetics of icatibant after single subcutaneous injection. This is an open-label, single-arm study that will enroll at least 12 Japanese subjects (in order to have 12 subjects complete the study), age 18-55 years inclusive. All subjects will receive a single subcutaneous injection of 30mg icatibant. The study will be conducted at 1 site in the US. The study will consist of a Screening Period, a Treatment Period, and a Follow-Up Period.

Interventions

Treatment arms and agents.

DRUG

Icatibant (30 mg)

On Day 1, subjects will receive a single 30mg subcutaneous injection of icatibant in their abdominal area. Subjects will be discharged from the study on Day 3 after collection of study related assessments

Timeline

From registration to results.

  1. First posted

    Jan 24, 2014

  2. Study start

    Feb 21, 2014

  3. Primary completion

    Feb 27, 2014

  4. Study completion

    Feb 27, 2014

  5. Results posted

    Jan 14, 2015

  6. Registry updated

    Jun 3, 2021

Outcomes

What the study measures.

Primary outcomes

Peak Plasma Concentration (Cmax) of Icatibant and Metabolites

Time frame · Over 48 hours post-dose

Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.

Time to Peak Plasma Concentration (Tmax) of Icatibant and Metabolites

Time frame · Over 48 hours post-dose

Tmax is the time after administration of a drug when the maximum plasma concentration in the body is reached.

Drug Concentration Half-Life (T1/2) of Icatibant and Metabolites

Time frame · Over 48 hours post-dose

The time it takes for the blood plasma concentration of a substance to halve.

Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUCinf) of Icatibant and Metabolites

Time frame · Over 48 hours post-dose

AUCinf is the area under the plasma concentration versus time curve extrapolated from time 0 to infinity, calculated using the observed value of the last non-zero concentration. AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.

Total Body Clearance (CL/F) of Icatibant

Time frame · Over 48 hours post-dose

The rate at which a drug is removed from the body.

Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Icatibant and Metabolites

Time frame · Over 48 hours post-dose

AUC0-t is the area under the plasma concentration versus time curve extrapolated from time 0 to to the last quantifiable concentration. AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.

Secondary outcomes

The Total Number of Treatment-Emergent Adverse Events

Time frame · TEAEs were collected after the single dose of icatibant until follow up, 5-7 days after icatibant administration

Treatment-emergent adverse events (TEAEs) were those that started after the single dose of icatibant.

The Percentage of Subjects With Any Injection Site Reactions.

Time frame · Over 48 hours post-dose

Safety Evaluation Measured by Percentage of Subjects With Not Clinically Significant Abnormalities in ECG Results

Time frame · Over 48 hours post-dose

Change From Baseline in Diastolic Blood Pressure

Time frame · Over 48 hours post-dose

Change From Baseline in Systolic Blood Pressure

Time frame · Over 48 hours post-dose

Change From Baseline in Pulse Rate

Time frame · Over 48 hours post-dose

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
55 Years
Sex
ALL
Healthy volunteers
Yes

Inclusion Criteria: 1. Healthy male and female volunteers, 18 to 55 years of age, inclusive; healthy status defined as absence of clinically significant findings in medical history or screening assessments 2. Japanese; defined as born in Japan, lived outside of Japan for no more than 10 years, and having Japanese parents and Japanese maternal and paternal grandparents 3. Body mass index of 18 to 28 kg/m2, inclusive Exclusion Criteria: 1. History of, or current, clinically significant disease and/or abnormalities 2. Smoking habit in excess of 5 cigarettes per day or the equivalent within 30 days of Day 1 or inability to refrain from smoking during the study confinement period 3. Subject has current abnormal thyroid function, as defined as abnormal screening thyroid stimulating hormone (TSH) and free thyroxine (T4). Treatment with a stable dose of thyroid medication for at least 12 weeks is permitted 4. History of drug allergy or other allergy that, in the opinion of the investigator, contraindicates participation 5. Male subjects who consume more than 21 units of alcohol per week or 3 units per day. Female subjects who consume more than 14 units of alcohol per week or 2 units per day. (1 alcohol unit =1 beer or =1 wine (5oz/150mL) or =1 liquor (1.5oz/40mL) or =0.75oz alcohol) 6. Routine consumption of more than 2 units of caffeine per day or subjects who experience caffeine withdrawal headaches. (1 caffeine unit is contained in the following items: one 6oz (180mL) cup of coffee, two 12oz (360mL) cans of cola, one 12oz cup of tea, three 1oz (85g) chocolate bars. Decaffeinated coffee, tea, or cola are not considered to contain caffeine) 7. Current use of any medication (including over-the-counter, herbal, or homeopathic preparations) with the exception of female hormonal replacement therapy or hormonal contraceptives. Occasional use of over-the-counter doses of ibuprofen or acetaminophen for minor self-limited pain (eg, headaches) is also acceptable. Current use is defined as use within 7 days of the first dose of investigational product\\ 8. Pregnant or lactating females

Study locations

1 registered sites.

United States. Showing up to 24 locations stored in the fast local snapshot.

PAREXEL

Glendale, California, United States

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

ClinicalTrials.gov ↗Search PubMed ↗Search FDA ↗Search EMA ↗

Related trials

More studies on Icatibant.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.

TrialsIcatibant trial dashboard →